Biblio Discovery — Demo Discovery Service

4 hasil untuk "D. Hartmann"

Menampilkan 1–4 · 0,54 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Refolding and characterization of two G protein-coupled receptors purified from E . coli inclusion bodies

    Bastian Heim; René Handrick; Marcus D. Hartmann dkk.

    PLOS ONE, Vol. 16 No. 2 · 2021 · Inggris · PLOS Scopus

    Aiming at streamlining GPCR production from E. coli inclusion bodies for structural analysis, we present a generic approach to assess and optimize refolding yield through thermostability analysis. Since commonly used hydrophobic dyes cannot be applied as probes for membrane protein unfolding, we…

  2. Artikel Jurnal Teks lengkap

    Structural Dynamics of the Cereblon Ligand Binding Domain

    Marcus D. Hartmann; Iuliia Boichenko; Murray Coles dkk.

    PLOS ONE, Vol. 10 No. 5 · 2015 · Inggris · PLOS Scopus

    Cereblon, a primary target of thalidomide and its derivatives, has been characterized structurally from both bacteria and animals. Especially well studied is the thalidomide binding domain, CULT, which shows an invariable structure across different organisms and in complex with different ligands…

  3. Artikel Jurnal Teks lengkap

    Lactoferrin Is an Allosteric Enhancer of the Proteolytic Activity of Cathepsin G

    Steffen Eipper; Robin Steiner; Adam Lesner dkk.

    PLOS ONE, Vol. 11 No. 3 · 2016 · Inggris · PLOS Scopus

    Protease-mediated degradation of proteins is critical in a plethora of physiological processes. Neutrophils secrete serine proteases including cathepsin G (CatG), neutrophile elastase (NE), and proteinase 3 (PR3) together with lactoferrin (LF) as a first cellular immune response against pathogens…

  4. Artikel Jurnal Teks lengkap

    A strategy to design protein-based antagonists against type I cytokine receptors

    Timo Ullrich; Olga Klimenkova; Christoph Pollmann dkk.

    PLOS Biology, Vol. 22 No. 11 · 2024 · Inggris · PLOS Scopus

    Excessive cytokine signaling resulting from dysregulation of a cytokine or its receptor can be a main driver of cancer, autoimmune, or hematopoietic disorders. Here, we leverage protein design to create tailored cytokine receptor blockers with idealized properties. Specifically, we aimed to tackle…